lunes, 17 de noviembre de 2014

Recent Therapeutic Advances in the Treatment of Colorectal Cancer. - PubMed - NCBI

Recent Therapeutic Advances in the Treatment of Colorectal Cancer. - PubMed - NCBI



 2014 Oct 9. [Epub ahead of print]

Recent Therapeutic Advances in the Treatment of Colorectal Cancer.

Abstract

Metastatic colorectal cancer is a prevalent disease for which novel targeted therapies and biologically based combinations are under development. Cytotoxic chemotherapy doublets (FOLFOX, FOLFIRI) and triplets (FOLFOXIRI) in combination with biologics are standard regimens, and efforts are ongoing to delineate the optimal sequence for each patient based on unique underlying tumor biology. Molecular profiling of metastatic colorectal cancer (including mutational analysis for KRAS, NRAS, BRAF, PIK3CA, and others) has become increasingly important for identification of prognostic and predictive biomarkers, as well as for insights into the biology that drives the tumor. Large comprehensive analyses such as that of The Cancer Genome Atlas have provided important clues into carcinogenesis and discerned potentially druggable targets for metastatic colorectal cancer. Novel therapeutic agents currently under investigation for subtypes of this disease include immunotherapies such as anti-programmed cell death receptor antibody, cancer stem cell inhibitors, targeted combinations such as BRAF and PI3K inhibitors, and the anti-RAS reovirus Reolysin.® Expected final online publication date for the Annual Review of Medicine Volume 66 is January 14, 2015. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.

PMID:
 
25341011
 
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario